AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01948791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENA713
Description: The following strengths of Rivastigmine capsules were provided: Rivastigmine capsule strengths: 1.5mg, 3mg, 4.5mg. The 6mg dose was administered as one 1.5mg capsule and one 4.5mg capsule, and when necessary, the 3mg dose could also be administered as two 1.5mg capsules. Rivastigmine was administered from 3mg/d at baseline. Then dose escalation was made in 3mg/d increments, at a minimun of 4 weeks between dose increases to a maximum dose of 12mg/d or the individual's best tolerated dose.
Study NCT01062516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole 20 mg daily
Description: oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
Study NCT01062516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: famotidine 40 mg daily
Description: oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
Study NCT00989391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654764
Description: 12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Study NCT03108027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Placebo (morning dose) and placebo (evening dose)
Description: Placebo (morning dose) and placebo (evening dose)
Study NCT01688479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil
Study NCT01688479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Essex® cream (Schering-Plough), aqueous cream without parabens
Study NCT02335918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of varlilumab and nivolumab
Description: Phase I: Varlilumab dosing will be dependent on the cohort assigned in combination with 3 mg/kg of nivolumab every two weeks.~Phase II: Patients with CRC, RCC or GBM enrolled in Phase ll will receive 3.0 mg/kg of varlilumab in combination with 240 mg of nivolumab every 2 weeks. Patients with SCCHN or ovarian cancer will receive varlilumab at a dose of either 3 mg/kg every 2 weeks, 3 mg/kg every 12 weeks, or 0.3 mg/kg every 4 weeks, in combination with 240 mg of nivolumab every 2 weeks.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects.
Study NCT00696774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.~Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more.
Study NCT02139176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contract referral
Description: A female partner signs a contract saying it is permissible for a community worker to trace a male sex partner in the community.
Study NCT02139176 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient referral
Description: A patient agrees to recruit their partner using the invitation.
Study NCT02139176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient referral
Description: A patient agrees to recruit their partner using the invitation.
Study NCT02401945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-120
Study NCT02987400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 3 cycles followed by 9 cycles consolidation if not transplant eligible
Study NCT02987400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 3 cycles followed by 9 cycles consolidation if not transplant eligible
Study NCT02232633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Study NCT02808026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Description: CS-3150 2.5 to 5mg, orally, once daily after breakfast
Study NCT00879281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action plan
Description: Individualized written Action Plan to enhance self-management and early detection of an exacerbation.
Study NCT04244279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic workshop
Description: Participants will participate in a single meeting workshop regarding ergonomic principles in baby care.
Study NCT04244279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brochure
Description: Participant will receive a brochure summarizing the main contents of the workshop.
Study NCT04244279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videos
Description: During the next three months after the beginning of the research, they will receive videos that will be a reminder of the principles learned in the workshop.
Study NCT00252954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levetiracetam
Description: Tablets 2000-3000 mg per day
Study NCT04210310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: The investigational product, oxytocin nasal spray (45 units/0.1mL for 38mL) is composed of: oxytocin powder (0.3080g), magnesium chloride crystals (2.3100g), citric acid anhydrous gran. (0.1080g), sodium citrate powder (2.1500g), sterile water for irrigation (38.000mL), and Pcca Mucolox liquid base (3.8000mL). Subjects will be asked to self-administer the study medication with 1 puff in one nostril 4 times per day
Study NCT00989391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654764
Description: 12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Study NCT03389815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-0593 Tablets
Description: tablets, dosage ranged from 30 mg to 300 mg, quaque die（QD）
Study NCT04588025 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-care Portable Perfusion Phantom, P4
Description: P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
Study NCT00989391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Study NCT04401956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bread
Description: Different types of bread
Study NCT04401956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bread
Description: Different types of bread
Study NCT01403545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Curcumin
Description: Single dose intravenous infusion of liposomal Curcumin at 10, 20, 40, 80, 120, 180 mg/m² over 120 minutes
Study NCT01403545 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% glucose infusion over 120 minutes
Study NCT04357509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Super circulating tumor infiltrating lymphocytes(ScTIL)
Description: Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion.
Study NCT02252809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Study NCT02252809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Study NCT00183963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20mg
Study NCT00183963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: 250mg
Study NCT00183963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: 500 mg IM
Study NCT02998047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lintuzumab AC 225
Description: Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.
Study NCT01294462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90 mg, oral dose twice daily
Study NCT01294462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75 mg, oral dose once daily
Study NCT01294462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid ASA
Description: Low Dose ASA
Study NCT01294462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid ASA
Description: Low Dose ASA
Study NCT00877305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 200 mmHg (at least a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line).
Study NCT00877305 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Sham intervention with four 5-min cycles of inflation of the blood pressure cuff at 20 mmHg and 5 min deflation without any upper leg ischaemia.
Study NCT03421301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary portfolio
Description: The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein and inulin) that was provided in dehydrated form in packages of 17.3 g dissolved in 250 ml water for breakfast and 34.7 g in 300 ml water for dinner.
Study NCT03421301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dietary portfolio
Description: The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein and inulin) that was provided in dehydrated form in packages of 17.3 g dissolved in 250 ml water for breakfast and 34.7 g in 300 ml water for dinner.
Study NCT04210310 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: A placebo nasal spray, consisting of magnesium, chloride crystals, citric acid anhydrous gran., sodium citrate powder, sterile water for irrigation, and Pcca Mucolox liquid base. Both active drug and the placebo will appear identical in the glass bottles. The placebo will be administered in the same manner as the active study drug, with 1 puff in one nostril four times per day.
Study NCT04465851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulphate 65 mg
Description: Oral ferrous salt supplement Ferrous Sulphate 200 mg (equiv. 65 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules
Study NCT04465851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous Sulphate 65 mg
Description: Oral ferrous salt supplement Ferrous Sulphate 200 mg (equiv. 65 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules
Study NCT04465851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: HydroCurc™ 500 mg formulated curcumin~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)
Study NCT04465851 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Ferrous Sulphate)
Description: Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)
Study NCT04465851 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Curcumin)
Description: Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)
Study NCT04465851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulphate 18mg
Description: Oral ferrous salt supplement~Ferrous Sulphate 55 mg (equiv. 18 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules
Study NCT04465851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ferrous Sulphate 18mg
Description: Oral ferrous salt supplement~Ferrous Sulphate 55 mg (equiv. 18 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules
Study NCT03993431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bio-active cement
Description: A cement used for crown cementation, specially recommended for pediatric esthetic crowns
Study NCT03993431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Packable glass ionomer
Description: Glass ionomer cement with improved mechanical properties usually used for restoration of simple small cavities and in Atraumatic Restorative Treatment
Study NCT06522048 — intervention group
Intervention type: OTHER
Intervention: Observational studies do not require intervention
Description: This is an observational retrospective study and does not require any intervention.
Study NCT00144924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy pyloromyotomy
Description: laparoscopic pyloromyotomy
Study NCT00144924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open pyloromytomy
Description: open pyloromyotomy
Study NCT02573246 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Restructuring
Description: Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.
Study NCT02573246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.
Study NCT02573246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS is a neurostimulation intervention where the participant receives 15 minutes of high frequency (10 HZ) transcranial magnetic stimulation pulses
Study NCT02573246 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS is a placebo intervention aimed to mimic the effects of repetitive transcranial magnetic stimulation with no known direct benefit for the participant.
Study NCT02087202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: magnesium sulfate is added to the patients
Study NCT02087202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: ketamine is added to the patients.
Study NCT04598126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/
Study NCT04598126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient education manual +traditional physical therapy
Description: Patient educational Manual~+ Traditional physical therapy Ultrasound posteriorly 6 mints 4 days/week hydrocollateral pack anteriorly 10 mints 4 days/week Quadriceps isometrics 10 repetitions×1 set, 4 days/week and Hamstring muscle strechings 10 repetitions×1 set, 4 days/
Study NCT02072187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active
Study NCT02072187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03503292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Rapid metabolizer will receive 1mg IV Granisetron
Study NCT03503292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Poor or normal metabolizers will receive 4mg Ondansetron IV
Study NCT01540409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-4658 (Eteplirsen)
Description: Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
Study NCT01049802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetititve transcranial magnetic stimulation
Description: 1 Hz rTMS to contralesional hemisphere in patients with stroke
Study NCT01049802 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetititve transcranial magnetic stimulation
Description: 1 Hz rTMS to contralesional hemisphere in patients with stroke
Study NCT00103519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DITPA (3,5-diiodothyropropionic acid)
Study NCT00103519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02228343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ayurveda
Description: Ayurveda includes meditation, yoga, breathing exercises, herbs
Study NCT01011933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01011933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study NCT00043823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 7.5 mg/kg By Vein on Day 1 of Every 21 Day Cycle
Study NCT00043823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: 100 mg By Mouth Daily for 3 Weeks
Study NCT03182595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Volunteers will be screened at visit 1, and if they meet the inclusion/exclusion criteria they will receive the intervention at visit 2. At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have a blood sample collected 2 hours after administration; these procedures will be repeated on 2 more occasions (visits 3 and 4). The subjects will come for 5 visits during the study. Visit 1 and 2 must occur within 7 days of each other, visits 2, 3 and 4 will be four weeks (± 3 days) apart and visit 5 scheduled four weeks (± 3 days) after visit 4.
Study NCT03454815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apical patency
Description: Apical patency was maintained by passing a #10 K file 1 mm beyond working length between every instrument change while doing chemomechanical preparation
Study NCT01873729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Adults with ADHD